Wedbush Has Positive Estimate for PTGX Q3 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Wedbush boosted their Q3 2025 earnings estimates for shares of Protagonist Therapeutics in a research report issued to clients and investors on Thursday, August 7th. Wedbush analyst Y. Zhong now forecasts that the company will post earnings per share of ($0.57) for the quarter, up from their previous forecast of ($0.62). The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. Wedbush also issued estimates for Protagonist Therapeutics’ Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($1.91) EPS, FY2026 earnings at ($2.67) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($0.35) EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). The business had revenue of $5.55 million for the quarter, compared to analysts’ expectations of $8.32 million. Protagonist Therapeutics had a return on equity of 8.12% and a net margin of 24.88%.

Several other brokerages have also recently weighed in on PTGX. Citigroup reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research note on Thursday. JMP Securities lifted their target price on shares of Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Finally, Wall Street Zen upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, June 8th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $67.20.

Protagonist Therapeutics Price Performance

Shares of Protagonist Therapeutics stock opened at $51.07 on Monday. The company’s fifty day simple moving average is $53.81 and its 200-day simple moving average is $47.43. The stock has a market capitalization of $3.18 billion, a PE ratio of 72.96 and a beta of 2.33. Protagonist Therapeutics has a 1-year low of $33.31 and a 1-year high of $60.60.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 10,415 shares of Protagonist Therapeutics stock in a transaction on Friday, July 25th. The shares were sold at an average price of $54.78, for a total value of $570,533.70. Following the sale, the chief executive officer directly owned 520,603 shares in the company, valued at approximately $28,518,632.34. The trade was a 1.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Arturo Md Molina sold 10,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total transaction of $570,300.00. Following the completion of the sale, the insider owned 83,892 shares in the company, valued at approximately $4,784,360.76. This represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,859 shares of company stock worth $4,020,877. 4.90% of the stock is currently owned by insiders.

Institutional Trading of Protagonist Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Deep Track Capital LP bought a new stake in shares of Protagonist Therapeutics in the 4th quarter worth about $38,600,000. Wellington Management Group LLP increased its holdings in shares of Protagonist Therapeutics by 3,025.4% in the 4th quarter. Wellington Management Group LLP now owns 940,077 shares of the company’s stock worth $36,287,000 after buying an additional 909,998 shares during the last quarter. BVF Inc. IL increased its holdings in shares of Protagonist Therapeutics by 35.5% in the 1st quarter. BVF Inc. IL now owns 2,575,015 shares of the company’s stock worth $124,528,000 after buying an additional 675,000 shares during the last quarter. New Vernon Capital Holdings II LLC increased its holdings in shares of Protagonist Therapeutics by 11,271.9% in the 1st quarter. New Vernon Capital Holdings II LLC now owns 348,095 shares of the company’s stock worth $16,834,000 after buying an additional 345,034 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Protagonist Therapeutics in the 1st quarter worth about $16,612,000. 98.63% of the stock is currently owned by institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.